Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 2025 Business Wire Strong margin improvement to 16.3% in FY 2025 Positive growth outlook with continued margin expansion in 2026 New EUR 200 million share buyback
Almirall’s 2025 Results Business Wire Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory. This revenue growth further advances Almirall’s leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM). The continued strong performance of the biologics portfolio is the backbone of Almirall’s growth, with Ilumetri® net sales increasing 12.3% YoY (total of €234.4 MM), and Ebglyss® net sales increasing more than 3x YoY to a total of €110.8 MM – reflecting its strong position and growth trajectory across Europe in the second year after launch. Continued solid performance of the broad dermatology product portfolio with Wynzora® growing 30.5% YoY to a total of €33.8 MM, and Klisyri® growing 33.9% YoY to a total of €32.8 MM, further enhances Almirall’s position as trusted partner for patients and dermatologists. Almirall’s business performance fuels the advancement of a diversified and innovative R&D pipeline addressing skin diseases with high unmet need. Pipeline progress in 2025 included the start of the phase II study of the anti-IL-1RAP mAb in Hidradenitis suppurativa, the start of the phase II study of the IL-2muFc in Alopecia areata, and the approval of Jublia® in Germany and Seysara® in China. Guidance for 2026: net sales growth of 9%-12% and total EBITDA between €270 MM and €290 MM.
De’ Longhi Group – Record Preliminary 2025 Revenues of €3.8 Billion, up 10.4% at Constant Exchange Rates The Group closed 2025 with brilliant results and solid growth at constant currency across both divisions throughout the year, further confirmed by an organic expansion of 8.2% in Q4
Quinbrook Sells Flexitricity to Drax January 21, 2026 Quinbrook, a specialist investment manager focused exclusively on delivering the infrastructure needed for the energy transition, today announced the sale of its Flexitricity energy optimisation business to Drax Smart Generation HoldCo Limited, a subsidiary of Drax Group plc (“Drax”). The agreed sale price generates expected total sale proceeds of c. £42 million which represents an [...]
Almirall Presents R&D Pipeline Advances Supported by Sustained Growth and Leadership in Medical Dermatology at J.P. Morgan Healthcare Conference January 16, 2026 Pipeline advances in 2026 span a range of dermatology disease areas, including atopic dermatitis, hidradenitis suppurativa, and alopecia areata, with 3 ongoing PoC/Phase II clinical studies* and 3 additional studies to be initiated in 2026. Almirall’s sustained trajectory of growth and profitability enables the company to reach more patients and supports a growth outlook of double-digit net sales through 2030, combined biologics peak sales of approximately €800 MM (Ebglyss® and Ilumetri®), and a 25% EBITDA margin by 2028. Almirall's leadership in medical dermatology, biologics growth, and continued strong performance of its broad product portfolio fuel advancement of a diversified and innovative R&D pipeline addressing skin diseases with high unmet need.
Titan Group: Financial Calendar 2026 November 26, 2025 Regulatory News: Titan S.A. (Euronext Brussels, ATHEX and Euronext Paris, TITC) announces its financial calendar for 2026. 19 March 2026 Publication of the fourth quarter and full year 2025 results 27 March 2026 Publication of the Integrated Annual Report 2025 7 May 2026 Publication of the first quarter 2026 results 7 May 2026 Annual General [...]
eDreams ODIGEO Sets New Accelerated Growth Target to Reach Over 13 Million Prime Members by 2030, 40% Above Market Consensus November 19, 2025 Building on the success of its 2021-2025 strategic plan, which quadrupled subscribers and delivered a 62-fold increase in Cash EBITDA, eDO presents its next phase of growth. From this position of strength, the new multi-year plan targets over 13 million Prime members by 2030, driven by accelerated +15-20% annual growth (FY28-FY30). Enhanced value proposition with the introduction of flexible monthly and quarterly subscription options, following successful tests and customer feedback showing higher NPS (+10%) and long-term value (+13%). Plan to accelerate eDO’s evolution into a global, diversified multi-product subscription, driven by investments in new products such as Rail and international expansion, targeting 66% of eDO volume from new areas by 2030 (up from 43%). Strong financial position enables continued investment in growth while continuing shareholder returns, aiming to invest €100 million in share repurchases over the next 2 years.
REPLY: The Board of Directors Approves the Quarterly Financial Report as of 30 September 2025 November 13, 2025 All economic indicators have substantially improved: Consolidated turnover of €1,819.8 million (1,669.6 as at 30 September 2024) EBITDA of €335.5 million (275.5 as at 30 September 2024) EBIT of €281.0 million (224.2 as at 30 September 2024) Pre-tax profit of €268.1 million (216.0 as at 30 September 2024) Positive Net Financial Position of €423.1 million.
Almirall’s 2025 9M Results November 10, 2025 Almirall continues its sustained growth trajectory in 9M 2025 - delivering 12.8% net sales growth, strong dermatology performance, solid commercial execution in Europe, and further pipeline progress Sustained strong growth momentum with 12.8% Net Sales YoY increase to a total of €820.7 MM, with biologics continuing to deliver double-digit growth YoY and dermatology sales in Europe increasing 24.5% YoY further advancing Almirall´s leadership in medical dermatology. EBITDA increase of 27.1% YoY in line with expectations, reaching a total of €180.7 MM. On track to meet 2025 guidance driven by biologics growth and operational strength. Performance continues to be primarily driven by the biologics portfolio, with Ilumetri® net sales increasing 12.1% YoY (total of €170.9 MM), and Ebglyss® net sales of €75.5 MM – reflecting a more than 3x increase YoY as European markets are ramping up after launch. Solid performance of the broad dermatology product portfolio with Wynzora® growing 32.4% YoY to a total of €25.4 MM, and Klisyri® growing 22.6% YoY to a total of €20.1 MM, further enhancing Almirall’s position as trusted partner for patients and dermatologists. Continued R&D pipeline progress includes the start of the phase II study of the anti-IL-1RAP mAb, and plan to initiate three additional proof-of-concept studies over the coming 9 to 12 months.
TITAN Group: Nine-Month 2025 Results November 6, 2025 Regulatory News: Titan SA (Euronext Brussels, ATHEX and Euronext Paris, TITC) announces the nine-month 2025 financial results. Record nine-month EBITDA profitability and a positive outlook Group Sales YTD increased by 1.4%, at €2,013m, thanks to the strong performance in Greece, in the US & in Egypt, driven by increased volumes and overall firm pricing levels. [...]